Pipeline· August 19, 2026 · 20 min read
Avexitide LUCIDITY Phase 3: What the First GLP-1 Antagonist Means for PBH Access
By Ran Chen#Pipeline#GLP-1#Clinical Evidence
Topic
Clinical Evidence
Trial design, endpoints, real-world evidence, safety updates, and how evidence translates into market access.
Pipeline· August 19, 2026 · 16 min read
INTerpath-001 Phase 3: Intismeran Autogene and Keytruda's Post-2028 Strategy
By Ran Chen#Pipeline#Clinical Evidence#Pivotal Trials
Policy· August 14, 2026 · 18 min read
FDA AEMS Explained: FAERS Replacement, Dashboard, & Safety Pipelines
By Ran Chen#Policy#FDA Approval#Clinical Evidence
Specialty· August 9, 2026 · 20 min read
Aesthetic Procedure Adverse Events by the Numbers (2026)
Policy· August 2, 2026 · 29 min read
EU Clinical Trials by the Numbers 2026: 12,123 CTIS Records Analyzed
By Ran Chen#Clinical Trials#EMA#Clinical Evidence
Deals· July 31, 2026 · 19 min read
argenx's $2.2B Forte Biosciences Deal: FB102 Anti-CD122 & Vyvgart Synergy
By Ran Chen#M&A#Immunology#Clinical Evidence
Pipeline· July 27, 2026 · 19 min read
Genome Editing Therapy Clinical Trials by the Numbers (2026)
By Ran Chen#Clinical Trials#Gene Editing#CRISPR
Pipeline· July 26, 2026 · 18 min read
Alzheimer's Disease Clinical Trials by the Numbers: 2026 Registry Analysis
Policy· July 26, 2026 · 18 min read
AMR Pipeline by the Numbers: FDA Antibacterials and the PASTEUR Act
Manufacturing· July 24, 2026 · 17 min read